As reported on Drugs, Eli Lilly has reported positive topline findings from two additional Phase 3 trials of retatrutide, its investigational triple hormone receptor agonist designed to target GIP, GLP-1,…
As reported on PharmaBiz, Ascletis Pharma has announced the submission of two Investigational New Drug (IND) applications to the US Food and Drug Administration (FDA) for experimental obesity treatments designed…
As reported by Yahoo Finance, the U.S. Food and Drug Administration (FDA) has accepted for review two applications from Sandoz for generic versions of tirzepatide, a GLP-1–based therapy currently marketed…
As reported on Becker's Hospital Review, the U.S. Food and Drug Administration (FDA) has issued updated guidance targeting how telehealth companies promote compounded medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists.…
As reported on Healio, emerging real-world evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—and related dual agonists—may play a significant role in lowering the risk of sleep apnea among individuals…
As reported on PharmaBiz, Vanda Pharmaceuticals has launched a new clinical trial, known as Thetis, to evaluate whether its neurokinin‑1 (NK‑1) receptor antagonist Nereus (tradipitant) can prevent vomiting associated with…
As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved Novo Nordisk’s higher‑dose formulation of semaglutide, Wegovy HD (7.2 mg once weekly), for chronic weight management. The…
A major clinical trial has revealed disappointing results for setmelanotide, a promising obesity treatment, when used in patients carrying single genetic mutations associated with weight gain. The EMANATE trial, conducted…
In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral small-molecule glucagon-like peptide‑1 (GLP‑1) receptor…
As reported on Healio, glucagon-like peptide-1 (GLP-1) receptor agonists, best known for treating diabetes and obesity, are emerging as unexpected players in breast cancer care. Data presented at the recent…
As reported by BioPharmaDive, he Food and Drug Administration (FDA) has intensified its oversight of companies marketing compounded GLP‑1 therapies, while Intellia Therapeutics, United Therapeutics, Merck & Co., and federal…
Patients using Zepbound for weight management now have a simpler option for administering their medication. As reported by PharmaLive.com, Eli Lilly received FDA clearance for a redesigned injection pen that…
Eli Lilly is making strategic moves to expand its obesity medication Zepbound beyond weight management, demonstrating promising results when combined with its autoimmune therapeutic Taltz for treating patients with both…
A first-of-its-kind Phase 3b study has shown that combining Eli Lilly’s Taltz (ixekizumab) with Zepbound (tirzepatide) delivers superior benefits for adults living with both active psoriatic arthritis (PsA) and obesity…
Roche has announced encouraging results from its Phase II trial of CT-388, an experimental obesity treatment that achieved placebo-adjusted weight loss of 22.5% over 48 weeks of treatment. This announcement…
A groundbreaking genetic study published in The Journal of Clinical Endocrinology & Metabolism and reported by ScienceDaily.com has revealed that obesity and high blood pressure don't simply increase dementia risk,…
In the shadows of his weight struggles, Sean Mulroney’s journey began at the staggering weight of 687 pounds in 2016. It was a weight that felt like a shackle, chaining…
A recent study has brought attention to the complex challenges faced by children with hidradenitis suppurativa (HS), a chronic and often painful skin condition. According to new research summarized by…
According to a story from drugs.com, the biopharmaceutical company Palatin Technologies, Inc., which is specializing in the development of therapies that interact with the melanocortin receptor system, recently announced the…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Bariatric surgery refers to surgical procedures that can help people with obesity to lose weight when other means have not worked. This type of surgery can help people to live…
The 59th Annual European Society for Paediatric Endocrinology (ESPE) Meeting is taking place virtually from September 22-26, 2021. During the Meeting, researchers are discussing best practices and treatments, as well…
According to a press release published on Globe Newswire, the biopharmaceutical company Saniona has announced recently that its investigational therapy Tesomet has recently earned Orphan Drug designation from the US…
According to MedPage Today, new research suggests that adult obesity could increase the risk of developing Crohn's disease. Within the study, researchers evaluated how body mass index (BMI) impacted the…
From June 4-8, 2021, the American Society of Clinical Oncology (ASCO) held its Annual Meeting to discuss trends and research within the oncology field. According to Cancer Therapy Advisor,…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
